Johnson & Johnson (NYSE:JNJ) Announces Quarterly Dividend of $1.34

Johnson & Johnson (NYSE:JNJ) declared a quarterly dividend on Tuesday, October 13th. Investors of record on Tuesday, November 24th will be given a dividend of $1.34 per share on Tuesday, December 8th. This represents a $5.36 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Tuesday, November 24th.

Johnson & Johnson has raised its dividend by an average of 0.1% per year over the last three years and has increased its dividend every year for the last 64 years. Johnson & Johnson has a dividend payout ratio of 48.3% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Johnson & Johnson to earn $12.33 per share next year, which means the company should continue to be able to cover its $5.36 annual dividend with an expected future payout ratio of 43.5%.

Johnson & Johnson Trading Down 5.6%

NYSE:JNJ opened at $248.90 on Wednesday. The stock has a market cap of $599.83 billion, a price-to-earnings ratio of 28.84, a price-to-earnings-growth ratio of 2.70 and a beta of 0.21. Johnson & Johnson has a one year low of $184.66 and a one year high of $281.07. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The business’s 50-day simple moving average is $265.89 and its 200 day simple moving average is $249.37.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%. The firm had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. During the same quarter last year, the firm earned $2.80 EPS. Johnson & Johnson’s quarterly revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 11.09 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on JNJ shares. Weiss Ratings upgraded Johnson & Johnson from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 8th. Raymond James Financial set a $280.00 price target on shares of Johnson & Johnson in a research report on Monday, August 3rd. Scotiabank restated an “outperform” rating and issued a $305.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. Stifel Nicolaus set a $260.00 price target on shares of Johnson & Johnson in a report on Wednesday, July 15th. Finally, HSBC increased their price objective on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $276.22.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.